Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | GLA | P06280 | 1/20 | 0.49 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 3/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.43 |
| ▸ | FNTB | P49356 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10503996 | 0.90 | GPR139 (0.46) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL10503368 | 0.90 | GPR139 (0.46) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL2673046 | 0.89 | CYP26A1 (0.48) | GAARAB9AALDH1A1CYP26A1CTSL | |
| SCHEMBL30843763 | 0.87 | GAA (0.53) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL9915089 | 0.86 | GAA (0.48) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL12019166 | 0.85 | GPR139 (0.47) | RAB9AALDH1A1LMNACTSLGPR139 | |
| SCHEMBL10805856 | 0.85 | PTPN1 (0.50) | LMNACTSLGPR139 | |
| SCHEMBL10942540 | 0.85 | PTPN1 (0.50) | LMNACTSLGPR139 | |
| SCHEMBL23154641 | 0.85 | GPR139 (0.45) | GAARAB9AALDH1A1LMNAGLA | |
| SCHEMBL28769012 | 0.85 | GPR139 (0.45) | GAARAB9AALDH1A1LMNAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | disclosed |
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | MEDICAL UNIVERSITY OF SOUTH CAROLINA | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046232-A1 | COMPOSITIONS AND METHODS FOR REDUCING RELAPSE OF ADDICTIVE BEHAVIOR | GRM6, GRM5, GRM7 | GAA 3387/4885RAB9A 1882/4885ALDH1A1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.